These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 25769314)

  • 1. Parkinson's disease and enhanced inflammatory response.
    Stojkovska I; Wagner BM; Morrison BE
    Exp Biol Med (Maywood); 2015 Nov; 240(11):1387-95. PubMed ID: 25769314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glial reactions in Parkinson's disease.
    McGeer PL; McGeer EG
    Mov Disord; 2008 Mar; 23(4):474-83. PubMed ID: 18044695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Contribution of Microglia to Neuroinflammation in Parkinson's Disease.
    Badanjak K; Fixemer S; Smajić S; Skupin A; Grünewald A
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Animal models of Parkinson's disease.
    Blandini F; Armentero MT
    FEBS J; 2012 Apr; 279(7):1156-66. PubMed ID: 22251459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis.
    Carvey PM; Punati A; Newman MB
    Cell Transplant; 2006; 15(3):239-50. PubMed ID: 16719059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidative and inflammatory pathways in Parkinson's disease.
    Miller RL; James-Kracke M; Sun GY; Sun AY
    Neurochem Res; 2009 Jan; 34(1):55-65. PubMed ID: 18363100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Inflammation and Parkinson's disease].
    Barcia González C; Herrero Ezquerro MT
    Rev Neurol; 2004 Mar 16-31; 38(6):545-53. PubMed ID: 15054720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention.
    Tansey MG; Goldberg MS
    Neurobiol Dis; 2010 Mar; 37(3):510-8. PubMed ID: 19913097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
    Urs NM; Bido S; Peterson SM; Daigle TL; Bass CE; Gainetdinov RR; Bezard E; Caron MG
    Proc Natl Acad Sci U S A; 2015 May; 112(19):E2517-26. PubMed ID: 25918399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.
    Morale MC; Serra PA; L'episcopo F; Tirolo C; Caniglia S; Testa N; Gennuso F; Giaquinta G; Rocchitta G; Desole MS; Miele E; Marchetti B
    Neuroscience; 2006; 138(3):869-78. PubMed ID: 16337092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of miR-124 in MPTP-treated mouse model of Parkinson's disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/cdk5 pathway proteins.
    Kanagaraj N; Beiping H; Dheen ST; Tay SS
    Neuroscience; 2014 Jul; 272():167-79. PubMed ID: 24792712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells.
    Jiang H; Ren Y; Yuen EY; Zhong P; Ghaedi M; Hu Z; Azabdaftari G; Nakaso K; Yan Z; Feng J
    Nat Commun; 2012 Feb; 3():668. PubMed ID: 22314364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuron-Astrocyte Interactions in Parkinson's Disease.
    Miyazaki I; Asanuma M
    Cells; 2020 Dec; 9(12):. PubMed ID: 33297340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidative stress and inflammation in Parkinson's disease: is there a causal link?
    Hald A; Lotharius J
    Exp Neurol; 2005 Jun; 193(2):279-90. PubMed ID: 15869932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonistic pleiotropic effects of nitric oxide in the pathophysiology of Parkinson's disease.
    Tripathy D; Chakraborty J; Mohanakumar KP
    Free Radic Res; 2015; 49(9):1129-39. PubMed ID: 25968946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An inflammatory review of Parkinson's disease.
    Orr CF; Rowe DB; Halliday GM
    Prog Neurobiol; 2002 Dec; 68(5):325-40. PubMed ID: 12531233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease.
    Chung YC; Kim SR; Jin BK
    J Immunol; 2010 Jul; 185(2):1230-7. PubMed ID: 20566832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease.
    Pérez-H J; Carrillo-S C; García E; Ruiz-Mar G; Pérez-Tamayo R; Chavarría A
    Toxicology; 2014 May; 319():38-43. PubMed ID: 24607817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroinflammation in Parkinson's disease: role in neurodegeneration and tissue repair.
    Vivekanantham S; Shah S; Dewji R; Dewji A; Khatri C; Ologunde R
    Int J Neurosci; 2015; 125(10):717-25. PubMed ID: 25364880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JNK inhibitor protects dopaminergic neurons by reducing COX-2 expression in the MPTP mouse model of subacute Parkinson's disease.
    Wang Y; Zhang Y; Wei Z; Li H; Zhou H; Zhang Z; Zhang Z
    J Neurol Sci; 2009 Oct; 285(1-2):172-7. PubMed ID: 19604516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.